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Ankylosing spondylitis (AS) is a common and highly heritable inﬂammatory arthropathy. Although the gene HLA-
B27 is almost essential for the inheritance of the condition, it alone is not sufﬁcient to explain the pattern of familial
recurrence of the disease. We have previously demonstrated suggestive linkage of AS to chromosome 2q13, a region
containing the interleukin 1 (IL-1) family gene cluster, which includes several strong candidates for involvement in
the disease. In the current study, we describe strong association and transmission of IL-1 family gene cluster single-
nucleotide polymorphisms and haplotypes with AS.
Introduction
Ankylosing spondylitis (AS [MIM 106300]) affects 1–9
in 1,000 British white individuals, making it one of the
most common causes of inﬂammatory arthritis after
rheumatoid arthritis (van der Linden et al. 1983; Braun
et al. 1998). The condition affects predominantly the
axial skeleton, including the spine and sacroiliac joints,
and causes pain, stiffness, and, eventually, bony anky-
losis. Joints and tendon insertions (entheses) elsewhere
are also commonly involved, and approximately one-
third of patients develop acute anterior uveitis.
Familial clustering has implicated genetic factors in
the disease etiology; heritability, as assessed by twin
studies, is 190% (Brown et al. 1997), and the sibling
recurrence risk ratio is 53–82 (Brown et al. 2000b). The
major susceptibility gene in AS is HLA-B27 (Brewerton
et al. 1973). HLA-B27 carriage is present in 195% of
white individuals with AS, yet only 1%–5% of HLA-
B27 carriers develop AS, and HLA-B27 carriage alone
does not explain the pattern of disease recurrence in
families (Brown et al. 2000b). Since familial AS is in
nearly all cases restricted to those carrying HLA-B27,
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it has been postulated that HLA-B27 is almost essential
but not adequate to cause AS and that other genes in-
teract with HLA-B27 to cause the condition (Brown et
al. 2002). Although several areas of suggestive or sig-
niﬁcant linkage have been reported from whole-ge-
nome scans, only one non-MHC gene, CYP2D6 (MIM
124030) on chromosome 22, has had replicated asso-
ciation reported with AS (Beyeler et al. 1996; Brown et
al. 2000a).
The chromosome 2q13 region was linked to AS in
our previously reported whole-genome screen (Laval et
al. 2001), with a maximum LOD score of 2.5 at a po-
sition 132 cM from the p-telomere. The magnitude of
the sibling recurrence risk due to this locus is lp 1.7
(95% CI 1.3–2.3), equivalent to 12% of the familiality
of AS. The interleukin 1 (IL-1) family gene cluster lies
123–126 cM from the p-telomere. Association of alleles
of the IL-1RN (MIM 147679) variable number of tan-
dem repeats (VNTR) with AS has been reported in some
studies (McGarry et al. 2001; van der Paardt et al. 2002)
but not others (Djouadi et al. 2001). Maksymowych et
al. (2003) demonstrated association between AS and
SNPs and SNP haplotypes within IL-1RN.
The prototypic members of the IL-1 family gene clus-
ter are the genes IL-1A (MIM 147760), IL-1B (MIM
147720), and IL-1RN. IL-1A and -B encode proinﬂam-
matory cytokines involved in host defense against in-
fection. The IL-1 receptor antagonist IL-1RA, encoded
by the gene IL-1RN, is an anti-inﬂammatory nonsig-
nalling molecule that competes for receptor binding
with IL-1a and IL-1b. Six genes with structural ho-
mology to IL-1A/B or IL-1RN lie between IL-1A and
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IL-1RN. They are named IL-1F5 (MIM 605507), IL-
1F6 (MIM 605509), IL-1F7 (MIM 605510), IL-1F8
(MIM 605508), IL-1F9 (MIM 605542), and IL-1F10;
IL-1A, IL-1B, and IL-1RN have been renamed IL-1F1,
IL-1F2, and IL-1F3, respectively (Sims et al. 2001). The
genes are ordered, from centromere to telomere, as IL-
1A, IL-1B, IL-1F7, IL-1F9, IL-1F6, IL-1F8, IL-1F5,
IL-1F10, IL-1RN, in a cluster within an ∼360-kb region
(Nicklin et al. 2002).
Given these ﬁndings and the prominent role of pro-
teins encoded by genes lying within this complex in
inﬂammation and in host defense against infection, we
sought to test whether IL-1 complex genes were asso-
ciated with AS. SNPs were identiﬁed in all nine IL-1
cluster gene members and, along with a VNTR in IL-
1RN, were genotyped in families and unrelated con-
trols. We demonstrate strong transmission disequilib-
rium of alleles and haplotypes of these markers in two
separate family collections and demonstrate association
by comparing cases from these families and unrelated
healthy controls. Our ﬁndings strongly suggest that the
IL-1 gene cluster contains a major susceptibility locus
for AS.
Subjects, Material, and Methods
Families and Control Individuals
We studied 227 white British families containing af-
fected sibling pairs and 317 parent-case trios with AS,
as well as 200 healthy blood donors. AS was deﬁned by
the modiﬁed New York diagnostic criteria (van der Lin-
den et al. 1984). The diagnosis of AS was conﬁrmed, in
all cases, by a qualiﬁed rheumatologist and was followed
by either examination or telephone interview (conducted
by L.B. or M.A.B.). In cases with an atypical history or
no previous radiographic evidence, pelvic and lumbo-
sacral spine radiographs were obtained and attending
general practitioners were contacted to conﬁrm diag-
nosis. All cases were HLA-B27 positive. There were 930
cases (66% male), who were, on average, 43.9 years of
age and had been affected for 21.6 years. The study was
approved by the Multicentre Research Ethics Commit-
tee, and all participants gave informed written consent.
SNP Identiﬁcation and Selection
We identiﬁed SNPs in the IL-1 gene cluster by using
a combination of literature searches and public SNP da-
tabases. IL-1A, IL-1B, and IL-1RN have previously
been extensively studied for polymorphisms and were
therefore not sequenced further. For the remaining six
genes, SNPs in exons, in exon-intron boundaries, or in
the 5′ UTR of each gene were identiﬁed from SNP da-
tabases and then were veriﬁed by direct sequencing in
48 healthy controls. An EST lying between IL-1F7 and
IL-1F9 (locus 129359) was also studied. Because of
strong linkage disequilibrium ( ) with other IL-′D 1 0.9
1RN markers, the SNPs IL-1RN8061 and IL-1RN9589
were not analyzed further. Twenty-ﬁve SNPs withminor-
allele frequencies 5% were used for the subsequent
studies, in addition to the IL-1RN VNTR.
Genotyping Methods
SNPs were genotyped either by SequenomMassArray
(Sequenom) or PCR/restriction digestion. The SNPs ge-
notyped and the respective genotyping methods are
given in table 1. Alleles of the IL-1RN 46-bp VNTR
were characterized by PCR and separation by electro-
phoresis on 2% agarose gels.
Statistical Analysis
Results were subjected to rigorous quality control. All
markers were genotyped in duplicate, and only consis-
tent genotypes were accepted. In the multicase and sin-
gle-case families, Mendelian inheritance was checked us-
ing the program GAS version 2 (A. Young, unpublished
software). MERLIN (Abecasis et al. 2002) was used to
identify unlikely recombination events suggestive of ge-
notyping error; such genotypes were repeated and re-
jected if the experimental data were still equivocal. Ge-
notype and allele frequencies were compared in the
probands of the multicase and single-case families.
Where these differed by 110%, the marker concerned
was regenotyped.
Initial analysis consisted of examination of within-
family association of single markers and two-marker
haplotypes of contiguous polymorphisms in parent-case
and affected-sibling-pair families, using TRANSMIT
(Clayton and Jones 1999). P values were determined by
bootstrap simulation, as implemented within TRANS-
MIT, to account for the linkage component when using
multicase families; signiﬁcance levels therefore reﬂect as-
sociation rather than linkage (Clayton and Jones 1999).
For each analysis, 106 simulations were performed, so
that the minimum P value reported is , which6P ! 10
we have recorded as . The TRANSMIT bootstrapPp 0
simulation method is described at the TRANSMIT Web
site.
To provide further support for these ﬁndings, a case-
control analysis was then performed, comparing allele
and genotype frequencies in probands from the affected-
sibling-pair families and parent-case trio families with
ﬁndings in unrelated healthy control individuals. In this
analysis, all markers were tested individually; speciﬁc
two-marker haplotypes were also assessed, as outlined
in the “Results” section. Haplotypes in unrelated control
samples were determined using the program PHASE
(Stephens and Donnelly 2003), a Bayesian haplotype re-
construction method; haplotypes were included in fur-
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Table 1
Markers Studied and the Genotyping Methods Employed
MARKER SNP ID
GENOTYPING
METHOD
PRIMERa
ENZYME/EXTENSION
PRIMERForward Reverse
IL-1A559 3783559 Digest tggtctctcatttgtctcatc tgttgcttgctcagtgttttg MseI
IL-1A376 2071376 Digest ccaagatgaagaccaaccag aggtcaggcagggaaaggaa BstY1
IL-1A889 1800587 Digest ctttaataatagtaaccaggcaaga gcccaaggtgtgtcttctgt DpnII
IL-1B3953 1143634 Digest gtaaataggctgaaaggggaaa gtaaataggctgaaaggggaaa TaqI
IL-1B5810 1143633 Digest gtatatgctcaggtgtcctc catggagaattagcaagctg Fnu4HI
IL-1B511 16944 Digest acttaagtttaggaatcttcccact gagcttatctccagggttgc AvaI
IL-1F7-1 2723187 Sequenom acgttggatggcattagcctcatccttgag acgttggatgaaactcccctttagagaccc ctctgcggagaaaggaagtc
IL-1F7-2 2708947 Sequenom acgttggatgtcttttatagggctcaggtg acgttggatgaattgcaggaggtgcagatg gggctcaggtgggctcc
LOCUS 129359 2708954 Digest agggctcactcgaatgactt atggggtaggaggagtgacc BspHI
IL-1F9-1 2121334 Sequenom acgttggatgagccagattgcaaagactag acgttggatgggtgaagtgaacattccctg tgcatggacatctacaaatggc
IL-1F6-1 1446512 Sequenom acgttggatgtctagagtccattgaggtgg acgttggatgatgctgcttctccatggaag gagctggctttgctacagtaa
IL-1F6-2 1446511 Sequenom acgttggatgagcttctcagagccactgtg acgttggatgtcaggagctggctttgctac gcatgctgcttctccatgg
IL-1F6-3 895497 Sequenom acgttggatgcacacccgatgattgatatc acgttggatgtgactttctcaacagcattg tgatatcctgaatgctcccc
IL-1F8-1 1562304 Sequenom acgttggatggtggaaaagaggcttgttag acgttggatgctctcctgttacacactcag gaggcttgttagagaggagg
IL-1F8-2 2197578 Digest ggactgacagtggagcaaca ggcctaacatcagatgcaaa BsmI
IL-1F8-3 1900287 Sequenom acgttggatgctacactgtgcaacttcagc acgttggatggggaaaatcatctgcatggg cttcagcctgcccacctta
IL-1F5-1 990524 Sequenom acgttggatgaagaaggaagaaagggaggg acgttggatgtcagaccctaagagtcagtg gaggcagggaggaaagaaagt
IL-1F5-2 2441375 Digest ggaaattgtgaccagcacct gagctctagactgggaggttcaatt MfeI
IL-1F5-3 1530548 Digest gtaagctcacccactctgtgcccgt acatgccagtgggtggac RsaI
IL-1F5-4 1374286 Sequenom acgttggatggtgggcaggtgcaaactatt acgttggatgattgttggacctcctgcttg tgcaaactattttagagagggac
IL-1F10-1 996878 Sequenom acgttggatggtctctttataggcctgctc acgttggatgcccaatctatcttggctcac aggcctgctcatagcatgg
IL-1F10-2 1446522 Sequenom acgttggatggaatctctggatcttgctcc acgttggatgccttcatcattctcctgcac tctggatcttgctccacagaa
IL-1F10-3 3811058 Digest caaggtggtgattcagagca gggaggaaagggaagaagag BsmAI
IL-1RN8006 419598 Digest ttctatctgaggaacaaccaactagtagc caccagacttgacacaggacaggca HpaII
IL-1RN8061b 423904 Digest acacaggaaggtgccaagca tgcagacagacgggcaaagt MwoI
IL-1RNVNTR Digest ctcagcaacactcctat tcctggtctgcaggtaa 46-bp repeat
IL-1RN9589b 454078 Digest ttgtggggaccaggggagat agcctggcactctgctgaat SspI
IL-1RN11100 315952 Digest agggaggcagcacaggactt agtccctgcagtccttgcca MspAI
a Underlined bases are deliberate mismatches.
b Studied in AS family probands only; not assessed further because of strong linkage disequilibrium with other IL-1RN markers ( ).′D 1 0.9
ther analysis if they were assigned 190% certainty. For
case-control haplotype comparisons, haplotypes were
determined in the parent-case trio and affected-sib-
ling-pair families through use of the program GENE-
HUNTER and proband haplotypes (i.e., one per family)
used for the cases (Kruglyak et al. 1996). Pairwise link-
age disequilibrium was calculated using the program
GOLD, through use of haplotype data from the healthy
controls (Abecasis and Cookson 2000).
Having demonstrated signiﬁcant association across
multiple polymorphisms in linkage disequilibrium with
one another, we employed stepwise conditional lo-
gistic regression (Cordell and Clayton 2002) and the
conditional extended transmission/disequilibrium test
(CETDT) (Koeleman et al. 2000) to determine whether
one or more SNPs could be identiﬁed as the primary as-
sociated variant(s). This analysis was performed using all
members of the parent-case trio and affected-sibling-pair
families. These methods use a conditional logistic regres-
sion approach to investigate the interdependence of as-
sociated physically linked markers. Markers are entered
or deleted from the conditional logistic regression equa-
tion in a stepwise manner, to determine whether a marker
is important once the effects of othermarkers have already
been accounted for. Phase-known genotype andhaplotype
relative risks (HRRs) can also be estimated without bias
when this approach is used (Cordell and Clayton 2002).
The CETDT can be considered to be a special case of the
conditional logistic regression in which the effect of alleles
is assumed to be multiplicative. The CETDT has the ad-
vantage of allowing for missing parental genotypes via an
EM algorithm, but this utility can be prohibitively slow
to implement when more than a few markers are being
considered simultaneously. Also, the CETDT does not
correct for any nonindependence between multiple af-
fected offspring from the same family, which is accounted
for within the stepwise conditional logistic regression
method by use of robust Huber-White information sand-
wich variance estimation, allowing all affected individuals
to be studied within multicase families.
Results
Within-family studies demonstrated signiﬁcant associa-
tion of both single-marker and two-marker haplotypes
for several markers spread across the IL-1 gene cluster
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Figure 1 Single-marker and two-marker haplotype TDTﬁndings
obtained using parent-case trios and multicase families.
Table 2
Within-Family TDT Results when Individual Markers and Two-
Marker Haplotypes Are Used
Marker One-Marker P Value Two-Marker P Valuea
IL-1A559 NS .022
IL-1A376 NS .003
IL-1A889 NS 0
IL-1B3953 .04 .0001
IL-1B5810 NS 0
IL-1B511 .00003 0
IL-1F7-1 NS NS
IL-1F7-2 NS .0003
LOCUS 129359 NS NS
IL-1F9-1 NS NS
IL-1F6-1 NS .002
IL-1F6-2 NS .0002
IL-1F6-3 NS .007
IL-1F8-1 .003 .02
IL-1F8-2 NS .000006
IL-1F8-3 .02 .0004
IL-1F5-1 .03 .05
IL-1F5-2 NS .03
IL-1F5-3 NS NS
IL-1F5-4 NS .05
IL-1F10-1 NS NS
IL-1F10-2 NS .007
IL-1F10-3 .003 NS
IL-1RN8006 NS NS
IL-1RNVNTR NS NS
IL-1RN11100 NS NS
NOTE.—NS p not signiﬁcant.
a Two-marker haplotypes consist of contiguous markers; P val-
ues are given with the 5′ marker of the two markers concerned.
(see table 2). Seven markers achieved signiﬁcance levels
of by within-family association. Two markersP ! .05
were sufﬁciently signiﬁcant to remain so once Bonfer-
onni correction was made for multiple (i.e., 26) com-
parisons (IL-1B511, ; IL-1F10-3,Pp .00003 Pp
). Two-marker haplotypes gave the strongest as-.00001
sociations, with 18 markers achieving , 6 ofP ! .05
which achieved (see ﬁg. 1 and table 2).6P ! 10
Case-control analysis conﬁrmed either genotypic or
allelic association for 10 markers (see table 3), all of
which had been associated with AS in the within-family
analysis, either as individual markers or as part of a
two-marker haplotype.
To determine which marker or combination of mark-
ers was primarily responsible for the observed associ-
ations, we employed a stepwise conditional logistic re-
gression approach (Cordell and Clayton 2002) (results
were similar when the CETDT was used [Koeleman et
al. 2000]). At the ﬁrst stage, each marker was entered
in turn into the regression equation, giving a 1-df test
for the effect at a marker without accounting for effects
at any other markers. This test is equivalent to per-
forming a transmission/disequilibrium test (TDT) anal-
ysis at each marker in turn, using all families for which
there are complete genotype data at the marker. Five
markers were associated with AS in this analysis (IL-
1B3953, IL-1B511, IL-1F6-2, IL-1F8-1, and IL-1F10-
3; , .0009, .047, .013, and .005 respectively).Pp .007
Each of these ﬁve markers, in turn, was accounted for
by including the marker in the regression equation, and
the effect of adding a second marker to the regression
equation was examined for all the remaining markers,
to test for their interdependence. Markers IL-1B511
and IL-1F10-3 remained signiﬁcant when added as sec-
ond markers in the regression equation, regardless of
which other of the ﬁve loci had been included as the
ﬁrst marker. If both of these markers were accounted
for, under the assumption of multiplicative effects of
haplotypes and applying Bonferroni correction for the
number of markers studied, no other marker showed
signiﬁcant association with AS. When multiplicative ef-
fects of haplotypes are assumed in families with both
parents genotyped, the combination of IL-1B511 and
IL-1F10-3 is signiﬁcantly associated with AS (Pp
). HRRs, signiﬁcance levels, and CIs are given in.0002
table 4. Once IL-1B511 was accounted for, IL-1F10-
3 remained signiﬁcantly associated ( ), and vicePp .002
versa ( ). Since this analysis used only familiesPp .0008
with both parents genotyped, the program TRANSMIT
was used to test the association of this marker combi-
nation in all available families (both parent-case trio
and affected-sibling-pair families). This demonstrated
highly signiﬁcant association ( ). Fur-8Pp 1.7 # 10
ther, when proband haplotypes established using the
program GENEHUNTER and control haplotypes iden-
tiﬁed using the program PHASE were compared, sig-
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Table 4
HRRs for Combination of SNPs
IL-1B5511 and IL-1F10-3 in Parent-Case
Trios, Relative to Haplotype 2-2
Haplotype HRR 95% CI P Value
1-1 11.3 2.6–49.8 .001
1-2 8.7 1.9–39.1 .005
2-1 5.8 1.3–27.5 .028
niﬁcant association of this haplotypes was also observed
( ).Pp .04
Linkage disequilibrium across the cluster was quite
variable and appears to form three main blocks (see
table 5). Moderate linkage disequilibrium was observed
between IL-1B511 and IL-1F10-3 ( ;′D p 0.27 Pp
)..01
Discussion
These results strongly indicate that a gene or combi-
nation of genes within the IL-1 gene cluster signiﬁcantly
inﬂuence susceptibility to AS. Several genetic studies
have hinted at association of the IL-1 region with AS
and, in particular, with polymorphisms of IL-1RN. Two
groups have previously reported association between al-
lele 2 of a VNTR in the IL-1RN gene and AS (McGarry
et al. 2001; van der Paardt et al. 2002). This polymor-
phism is associated with lower levels of IL-1RA pro-
duction. Recently, Maksymowych and colleagues re-
ported strong association of haplotypes of three SNPs
within the 3′ region of the IL-1RN gene with AS, but
they did not study the IL-1RN VNTR (Maksymowych
et al. 2003). The fact that the haplotypic ﬁndings were
stronger than individual SNP associations suggests either
that these markers were not themselves involved in AS
or that they acted in combination. Our ﬁndings do not
demonstrate association of the IL-1RN VNTR with AS,
nor do they demonstrate association of the other SNPs
or haplotypes of polymorphisms within IL-1RN with
the disease, making it unlikely that variation in this gene
is responsible for the strong association we saw else-
where in this region. Previous positive ﬁndings at this
locus may be due to linkage disequilibrium with the
associated haplotypes that we report here. Extensive
linkage disequilibrium was seen across the IL-1 gene
cluster (see ﬁg. 2), and, thus, associations may be seen
at loci physically quite remote from the true associated
variant(s).
The genes IL-1A, IL-1B, and IL-1RN have been ex-
tensively sequenced in the past, and comprehensive data
on their polymorphisms are available in public data-
bases (University of Washington–Fred Hutchinson Can-
cer Research Center [UW-FHCRC] Variation Discovery
Resource Web site). Much less is known about genes
IL-1F5–F10, including information about polymor-
phisms, expression patterns in tissues and disease, or
function. The different IL-1 family members signal
through a range of IL-1 receptors, with IL-1a/b signal-
ling through IL-1R1 and IL-1R2, IL1-F6 signalling
through IL-1R6, and IL-18 signalling through IL-1R5.
IL-1F5 inhibits IL-1F6 activity, and IL-1F7 inhibits IL-
18 activity. IL-1F8, -9, and -10 are thought to be IL-1
antagonists, since their sequences are most similar to
IL-1RN, but their exact function is undetermined. IL-
1F10 binds IL-1R1, suggesting that it may play a role
in regulating IL-1A/B function (Smith et al. 2000). Al-
though it appears that IL-1a, IL-1b, and IL-1RA are
expressed at greater levels than other IL-1 gene family
members, they are all widely expressed, including on
activated monocytes and B cells (Laurincova 2000;
Smith et al. 2000)
Very little is known about the role of IL-1 in anky-
losing spondylitis. Using in situ hybridization methods,
Braun et al. (1995) found no IL-1 mRNA in sacroiliac
joint biopsy specimens from three patients with AS.
There are contradictory ﬁndings regarding serum IL-1b
levels, with studies showing either increased IL-1b levels
in serum from patients with AS compared with healthy
controls (Vazquez-Del et al. 2002) or no difference com-
pared with controls with noninﬂammatory back pain
(Gratacos et al. 1994). Stimulation of blood cell cultures
with the superantigen Mycoplasma arthritidis super-
natant suggested that AS cases had impaired IL-1B pro-
duction (Brand et al. 1997). Expression patterns of
other IL-1 family members in AS have not been
reported.
Our results point to the presence of one or more sus-
ceptibility loci within the IL-1 complex, marked by the
IL-1B511 and IL-1F10-3 polymorphisms. Linkage
disequilibrium is signiﬁcant across the entire IL-1 gene
cluster, perhaps explaining the broad area across which
we observed association. Conditional logistic regression
analysis demonstrated that IL-1B511 and IL-1F10-3
were consistently associated with disease even when the
inﬂuence of other associated markers was controlled for.
Haplotypes of these two markers were strongly asso-
ciated with disease both within families ( inPp .0002
the fully typed parent-case trio and affected-sib-pair
families; among all families) and by8Pp 1.7 # 10
case-control analysis ( ). Signiﬁcant residual as-Pp .04
sociation was noted when either of these markers was
accounted for, suggesting either that there is one locus
with a susceptibility allele that lies on more than one
haplotype or that there is more than one susceptibility
locus for AS within the IL-1 family gene cluster. The
fact that the associations observed were strongest for
haplotypes rather than individual SNPs suggests that
the markers reported here either are not themselves
causally associated with AS or encode only part of the
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susceptibility effect demonstrated in this region. We
have initiated further mapping studies to identify the
true disease-causing variants, which could have signif-
icant implications for the development of novel thera-
peutic targets.
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